verteporfin, bevacizumab, triamcinolone acetonide — Competitive Intelligence Brief

verteporfin, bevacizumab, triamcinolone acetonide (verteporfin, bevacizumab, triamcinolone acetonide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: photosensitizer, monoclonal antibody, corticosteroid. Area: Ophthalmology, Oncology.

phase 3 photosensitizer, monoclonal antibody, corticosteroid VEGF-A, VEGF receptor Ophthalmology, Oncology Small molecule

Target snapshot

verteporfin, bevacizumab, triamcinolone acetonide (verteporfin, bevacizumab, triamcinolone acetonide) — Shahid Beheshti University of Medical Sciences. Verteporfin is a photosensitizer that selectively targets and destroys abnormal blood vessels in the eye, while bevacizumab is a monoclonal antibody that inhibits angiogenesis by targeting vascular endothelial growth factor A (VEGF-A), and triamcinolone acetonide is a corticosteroid that reduces inflammation and swelling.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
verteporfin, bevacizumab, triamcinolone acetonide TARGET	verteporfin, bevacizumab, triamcinolone acetonide	Shahid Beheshti University of Medical Sciences	phase 3	photosensitizer, monoclonal antibody, corticosteroid	VEGF-A, VEGF receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (photosensitizer, monoclonal antibody, corticosteroid class)

1. Shahid Beheshti University of Medical Sciences · 1 drug in this class